Vail Resorts reported Q4 earnings per share of -$5.34, slightly better than expected, with revenue of $278.1 million surpassing estimates. The company benefited from a 5.2% rise in mountain revenues, driven by strong pass sales in Australia and stable summer demand, offsetting weak winter conditions elsewhere. Vail Resorts aims to improve profitability through $106 million in annualized operational efficiencies. These results highlight resilience in its leisure business despite seasonal challenges.
Vail Resorts reported Q4 revenue of $278.1 million, exceeding expectations and supported by a 5.2% rise in mountain revenues. For readers following the Consumer Cyclical sector, here is Pluang's market snapshot as of Sep 29, 2026 03:12 WIB: Of 112 priced US stocks, 50 rose and 60 fell. Notable movers include RENT at USD 1.60 with 61% buy order activity, TSLA at USD 357.17 with 61% sell order activity, and LCID at USD 3.91 with 86% buy order activity.
Lifecore Biomedical's stock surged 55.24% to $6.52 after announcing an acquisition by Webster Equity Partners offering $6.28 per share in cash plus potential Contingent Value Rights up to $9.67 per share. The deal values the company at up to $663.7 m...
A director of Espey Manufacturing and Electronics Corp sold 100 shares at $64.49 each, reducing his holdings to 20,550 shares. This insider sale happened after the company reported strong 2026 financial results, including net sales growth to $46.1 mi...
Conagra Brands is set to report Q1 earnings with analysts forecasting a 1.4% revenue decline to about $2.59 billion due to weak consumer spending and inflation. Earnings per share are expected to drop 20.5% to $0.31, reflecting margin pressures and a...
Morgan Stanley raised the price target for Reinsurance Group of America (RGA) to $295, implying a 16.7% upside from its current price of $252.85. The company reported a 42% increase in adjusted operating income to $746 million in H1, driven by its lo...
H.C. Wainwright raised Mirum Pharmaceuticals' price target from $140 to $195 following positive developments: the Phase 3 AZURE-1 trial for Brelovitug met its main goal for treating Chronic Hepatitis Delta Virus, and the FDA approved Atebrioz™ for Fi...
